Cox Ij

List of Publications by Year
in descending order

63	3,269	147801	149698
papers	citations	31 h-index	56 g-index

64	64	64	4868
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Chronically elevated branched chain amino acid levels are pro-arrhythmic. Cardiovascular Research, 2022, 118, 1742-1757.	3.8	24
2	Mapping of population disparities in the cholangiocarcinoma urinary metabolome. Scientific Reports, 2021, 11, 21286.	3.3	2
3	Characterisation of the Serum Metabolic Signature of Cholangiocarcinoma in a United Kingdom Cohort. Journal of Clinical and Experimental Hepatology, 2020, 10, 17-29.	0.9	12
4	Metabolomics and microbial composition increase insight into the impact of dietary differences in cirrhosis. Liver International, 2020, 40, 416-427.	3.9	13
5	A Double-Blind, Randomized Placebo-Controlled Trial of Probiotic Lactobacillus casei Shirota in Stable Cirrhotic Patients. Nutrients, 2020, 12, 1651.	4.1	27
6	Cholangiocarcinoma: a guide for the nonspecialist. International Journal of General Medicine, 2019, Volume 12, 13-23.	1.8	67
7	Mass Spectrometry: A Guide for the Clinician. Journal of Clinical and Experimental Hepatology, 2019, 9, 597-606.	0.9	8
8	Microbial functional change is linked with clinical outcomes after capsular fecal transplant in cirrhosis. JCI Insight, 2019, 4, .	5.0	49
9	Alterations in gut microbial function following liver transplant. Liver Transplantation, 2018, 24, 752-761.	2.4	63
10	The Plasma and Serum Metabotyping of Hepatocellular Carcinoma in a Nigerian and Egyptian Cohort using Proton Nuclear Magnetic Resonance Spectroscopy. Journal of Clinical and Experimental Hepatology, 2017, 7, 83-92.	0.9	4
11	Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. Hepatology, 2017, 66, 1727-1738.	7.3	454
12	Reply. Hepatology, 2017, 66, 1355-1356.	7.3	0
13	The Quest for Relevant Hepatocellular Carcinoma Biomarkers. Cellular and Molecular Gastroenterology and Hepatology, 2017, 4, 283-284.	4.5	7
14	A longitudinal study of patients with cirrhosis treated with L-ornithine L-aspartate, examined with magnetization transfer, diffusion-weighted imaging and magnetic resonance spectroscopy. Metabolic Brain Disease, 2017, 32, 77-86.	2.9	6
15	Urinary metabolic profiling by 1H NMR spectroscopy in patients with cirrhosis may discriminate overt but not covert hepatic encephalopathy. Metabolic Brain Disease, 2017, 32, 331-341.	2.9	6
16	Urinary nuclear magnetic resonance spectroscopy of a Bangladeshi cohort with hepatitis-B hepatocellular carcinoma: A biomarker corroboration study. World Journal of Gastroenterology, 2016, 22, 4191.	3.3	26
17	Hepatocellular carcinoma: Review of disease and tumor biomarkers. World Journal of Hepatology, 2016, 8, 471.	2.0	58
18	Hepatic steatosis and fibrosis: Non-invasive assessment. World Journal of Gastroenterology, 2016, 22, 9880.	3.3	62

#	Article	IF	Citations
19	Urinary Metabotyping of Hepatocellular Carcinoma in a UK Cohort Using Proton Nuclear Magnetic Resonance Spectroscopy. Journal of Clinical and Experimental Hepatology, 2016, 6, 186-194.	0.9	13
20	Magnetic Resonance Spectroscopy: Principles and Techniques: Lessons for Clinicians. Journal of Clinical and Experimental Hepatology, 2015, 5, 320-328.	0.9	71
21	Magnetic Resonance Imaging: Principles and Techniques: Lessons for Clinicians. Journal of Clinical and Experimental Hepatology, 2015, 5, 246-255.	0.9	250
22	¹H NMR Metabolic Profiling of Plasma Reveals Additional Phenotypes in Knockout Mouse Models. Journal of Proteome Research, 2015, 14, 2036-2045.	3.7	10
23	Loss of arylformamidase with reduced thymidine kinase expression leads to impaired glucose tolerance. Biology Open, 2015, 4, 1367-1375.	1.2	13
24	The role of intestinal microbiota in murine models of acetaminophenâ€induced hepatotoxicity. Liver International, 2015, 35, 764-773.	3.9	46
25	Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function. American Journal of Physiology - Renal Physiology, 2014, 307, G951-G957.	3.4	125
26	Metabolic Profiling of the Rat Liver After Chronic Ingestion of Alpha-Naphthylisothiocyanate Using In Vivo and Ex Vivo Magnetic Resonance Spectroscopy. Toxicological Sciences, 2012, 126, 306-316.	3.1	4
27	Serum Metabolic Profiling in Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2012, 57, 2157-2165.	2.3	84
28	Lipid profiling of preâ€treatment liver biopsy tissue predicts sustained virological response in patients with chronic hepatitis C. Hepatology Research, 2012, 42, 714-720.	3.4	3
29	Urinary Metabolic Biomarkers of Hepatocellular Carcinoma in an Egyptian Population: A Validation Study. Journal of Proteome Research, 2011, 10, 1828-1836.	3.7	88
30	A comparison of singleâ€voxel clinical in vivo hepatic ³¹P MR spectra acquired at 1.5 and 3.0 Tesla in health and diseased states. NMR in Biomedicine, 2011, 24, 231-237.	2.8	15
31	Differences in gut microbial metabolism are responsible for reduced hippurate synthesis in Crohn's disease. BMC Gastroenterology, 2010, 10, 108.	2.0	93
32	Metabolic profiling of bile in cholangiocarcinoma using in vitro magnetic resonance spectroscopy. Hpb, 2010, 12, 396-402.	0.3	45
33	Characterization of Urinary Biomarkers of Hepatocellular Carcinoma Using Magnetic Resonance Spectroscopy in a Nigerian Population. Journal of Proteome Research, 2010, 9, 1096-1103.	3.7	75
34	Hepatic lipid profiling in chronic hepatitis C: An in vitro and in vivo proton magnetic resonance spectroscopy study. Journal of Hepatology, 2010, 52, 16-24.	3.7	38
35	Characterization of Inflammatory Bowel Disease With Urinary Metabolic Profiling. American Journal of Gastroenterology, 2009, 104, 1435-1444.	0.4	163
36	Polychlorinated biphenyls in bile of patients with biliary tract cancer. Chemosphere, 2009, 76, 841-846.	8.2	12

#	Article	IF	Citations
37	Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Review of Gastroenterology and Hepatology, 2009, 3, 353-367.	3.0	259
38	Phenotyping murine models of non-alcoholic fatty liver disease through metabolic profiling of intact liver tissue. Clinical Science, 2009, 116, 403-413.	4.3	30
39	In vitroproton magnetic resonance spectroscopy of liver tissue informsin vivohepatic proton magnetic resonance spectroscopy studies. Hepatology, 2008, 48, 1016-1016.	7.3	5
40	Metabonomics in hepatic encephalopathy: lucidity emerging from confusion. Liver International, 2008, 28, 1050-1051.	3.9	5
41	Proton and phosphorus-31 nuclear magnetic resonance spectroscopy of human bile in hepatopancreaticobiliary cancer. European Journal of Gastroenterology and Hepatology, 2005, 17, 733-738.	1.6	43
42	In vivo and in vitro nuclear magnetic resonance spectroscopy as a tool for investigating hepatobiliary disease: a review of 1H and 31P MRS applications. Liver International, 2005, 25, 273-281.	3.9	36
43	p53 mutations in human cholangiocarcinoma: a review. Liver International, 2005, 25, 704-716.	3.9	64
44	Hypothermia and Amiloride Preserve Energetics in a Neonatal Brain Slice Model. Pediatric Research, 2005, 58, 288-296.	2.3	12
45	The Application of Magnetic Resonance Imaging and Spectroscopy to Gene Therapy. Methods in Enzymology, 2004, 386, 303-313.	1.0	4
46	¹H magnetic resonance spectroscopy of preinvasive and invasive cervical cancer: In vivoâ€“ex vivo profiles and effect of tumor load. Journal of Magnetic Resonance Imaging, 2004, 19, 356-364.	3.4	55
47	¹H magnetic resonance spectroscopy of invasive cervical cancer: an in vivo study with ex vivo corroboration. NMR in Biomedicine, 2004, 17, 1-9.	2.8	70
48	Preinvasive and invasive cervical cancer: anex vivo proton magic angle spinning magnetic resonance spectroscopy study. NMR in Biomedicine, 2004, 17, 144-153.	2.8	34
49	Altered mitochondrial function and cholesterol synthesis influences protein synthesis in extended HepG2 spheroid cultures. Archives of Biochemistry and Biophysics, 2004, 432, 167-177.	3.0	11
50	In vitro 1H-magnetic resonance spectroscopy of Barrett's esophageal mucosa using magic angle spinning techniques. European Journal of Gastroenterology and Hepatology, 2004, 16, 1199-1205.	1.6	10
51	Brain alkaline intracellular pH after neonatal encephalopathy. Annals of Neurology, 2002, 52, 732-742.	5.3	81
52	Characterization of Cerebral White Matter Damage in Preterm Infants Using 1H and 31P Magnetic Resonance Spectroscopy. Journal of Cerebral Blood Flow and Metabolism, 2000, 20, 1446-1456.	4.3	60
53	Relation between proton magnetic resonance spectroscopy within 18 hours of birth asphyxia and neurodevelopment at 1 year of age. Developmental Medicine and Child Neurology, 1999, 41, 76-82.	2.1	92
54	A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson's disease. Metabolic Brain Disease, 1999, 14, 45-55.	2.9	50

#	Article	IF	Citations
55	Effects of fish oil on phospholipid metabolism in human and rat liver studied by31P NMR spectroscopyin vivo andin vitro. NMR in Biomedicine, 1993, 6, 157-162.	2.8	11
56	A 31P and 1H-NMR investigation in vitro of normal and abnormal human liver. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1993, 1225, 71-77.	3.8	81
57	In vivo andin vitro31P magnetic resonance spectroscopy of focal hepatic malignancies. NMR in Biomedicine, 1992, 5, 114-120.	2.8	40
58	31P magnetic resonance spectroscopy of the normal human brain: approaches using four dimensional chemical shift imaging and phase mapping techniques. NMR in Biomedicine, 1989, 1, 190-197.	2.8	28
59	Four-dimensional phosphorus-31 chemical shift imaging of carcinoid metastases in the liver. NMR in Biomedicine, 1988, 1, 56-60.	2.8	26
60	Spectral resolution in clinical magnetic resonance spectroscopy. Magnetic Resonance in Medicine, 1987, 5, 186-190.	3.0	12
61	Medium effects on33S NMR of inorganic sulphate. Magnetic Resonance in Chemistry, 1986, 24, 171-174.	1.9	11
62	Experimental sulphur-33 nuclear magnetic resonance spectroscopy. Journal of the Chemical Society, Faraday Transactions 2, 1985, 81, 63.	1.1	101
63	Central Nervous System Complications. , 0, , 482-495.		0